Saturday 17 October 2026
Export SERA’s income statement to Excel — free account
Sera Prognostics, Inc.
SERA Healthcare Medical Devices
Sera Prognostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $81,000.00, up 5.19% from fiscal 2024. In the quarter to June 2026, revenue grew 76.5%, EPS fell 12.5% and free cash flow fell 10.6%, each against the same quarter a year earlier.
2.06
0.03
+1.48%
Follow SERA
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | 4 | 3 | 4 | 2 | 4 |
Altman Z-Score |
— | — | — | 5.76 | (1.71) | (0.10) | (0.15) | (2.09) |
P/S ratio |
— | 537.93 | 537.93 | 1,256.97 | 151.25 | 608.72 | 2,287.26 | 1,735.84 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | (21.67) | (35.81) | 16.42 | 1.64 | (5.79) | (11.87) | (8.32) |
Beneish M-Score |
— | — | (26.31) | 453.88 | (1.09) | (2.25) | — | — |
P/Operating CF |
— | (3.79) | (3.79) | (11.26) | (5.60) | (27.53) | (43.11) | (22.97) |
P/B ratio |
— | 0.00 | 0.00 | 0.74 | 0.41 | 2.66 | 5.65 | 1.86 |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.74 | 0.41 | 2.66 | 5.77 | 1.89 |
EV/Sales |
— | (1,524.79) | (1,524.79) | (24.26) | (155.01) | 448.97 | 1,895.45 | 1,251.90 |
EV/EBITDA |
— | 3.09 | 3.09 | 0.06 | 0.93 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | 3.15 | 3.15 | 0.06 | 1.20 | (5.05) | (15.76) | (3.96) |
EV/FCF |
— | 3.11 | 3.11 | 0.06 | 1.17 | (5.09) | (14.63) | (3.70) |
Quick Ratio |
— | 3.62 | 1.20 | 12.87 | 5.72 | 2.48 | 1.87 | 1.62 |
Current Ratio |
— | 3.65 | 1.22 | 13.11 | 5.80 | 2.51 | 1.92 | 1.69 |
Net Debt/EBITDA |
— | (6.74) | 0.55 | 3.02 | 1.83 | 1.26 | 1.29 | 1.10 |
Debt/Assets |
0.00% | 544.58% | 28.05% | 0.04% | 0.54% | 0.21% | 0.00% | 0.00% |
Debt/Equity |
— | (1.19) | 1.68 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 1.17 | 0.85 | 0.90 | 0.78 | 0.75 | 0.43 | 0.80 |
Capex/Depreciation |
— | 0.00 | (0.17) | (1.98) | (1.03) | 0.20 | (1.32) | (0.77) |
Interest Coverage |
— | (16.28) | (9.77) | (47.45) | (748.39) | (724.02) | (1,308.39) | (4,056.00) |
| — | 14.23% | 17.10% | (538.85%) | (37.21%) | (42.86%) | (55.78%) | (51.83%) | |
| — | (142.06%) | (104.31%) | (43.27%) | (33.56%) | (34.23%) | (39.16%) | (36.59%) | |
ROIC |
— | 0.00% | 0.00% | (66.03%) | (169.18%) | (116.98%) | (1,459.33%) | (63.01%) |
Return on Tangible Assets |
— | (95.59%) | (574.31%) | (33.79%) | (56.91%) | (93.17%) | (136.68%) | (180.07%) |
Average Days of Receivables |
— | 10.14 | 29.20 | 13,990.18 | 8,325.54 | 13,681.54 | 161.17 | 54.07 |
Research and Development Expense of Revenue |
— | 25,980.56% | 31,128.00% | 13,437.80% | 5,314.93% | 4,975.49% | 19,129.87% | 16,260.49% |
Selling, General and Administrative Expense of Revenue |
— | 17,486.11% | 40,812.00% | 29,781.71% | 11,747.39% | 8,069.28% | 28,441.56% | 28,703.70% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
— | 0.00% | 2,904.00% | 3,817.07% | 1,886.19% | 1,723.20% | 9,107.79% | 6,308.64% |
Graham Net Nets |
— | 3.70 | 3.70 | 0.99 | 1.79 | 0.19 | 0.08 | 0.10 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (110.12%) | (110.12%) | (109.44%) | (109.16%) | (19.43%) | (12.16%) | (23.05%) |
Free Cash Flow Yield |
— | (91.04%) | (91.04%) | (31.96%) | (87.29%) | (14.50%) | (5.67%) | (19.48%) |
Revenue per Share |
— | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.63) | (10.84) | (2.11) | (1.12) | (0.87) | (0.43) | (0.54) |
Capex per Share |
— | 0.00 | (0.10) | (0.09) | (0.02) | 0.01 | (0.03) | (0.02) |
Free Cash Flow per Share |
— | (0.63) | (10.94) | (2.20) | (1.14) | (0.87) | (0.46) | (0.55) |
Cash per Share |
— | 0.70 | 8.70 | 7.01 | 2.67 | 1.57 | 1.39 | 0.82 |
Shareholders Equity per Share |
— | (3.47) | 1.59 | 9.24 | 3.20 | 2.25 | 1.44 | 1.58 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (3.47) | 1.59 | 9.24 | 3.20 | 2.25 | 1.44 | 1.58 |
Free Cash Flow |
— | (19.32) | (17.02) | (32.94) | (35.38) | (27.00) | (15.29) | (26.35) |
Working Capital |
— | 15.65 | 2.49 | 101.84 | 74.59 | 36.90 | 22.83 | 16.58 |
Capital Expenditures |
— | (0.11) | (0.15) | (1.30) | (0.77) | 0.18 | (1.10) | (0.73) |
Net Current Asset Value |
— | (108.33) | 1.40 | 101.79 | 72.74 | 36.06 | 22.83 | 14.25 |
EV/EBIT |
— | 3.00 | 3.00 | 0.06 | 0.91 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 5.96 | 15.90 | 2.89 | (0.60) | 14.30 | 8.96 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.58 | 0.93 | 0.37 | 0.25 | 0.45 | 0.67 | 0.82 |
Cash ROIC |
— | (46.64%) | (84.45%) | (13.51%) | (19.41%) | (22.61%) | (16.26%) | (22.99%) |
Accounts Receivable Turnover |
— | 24.00 | 16.67 | 0.05 | 0.06 | 0.03 | 0.01 | 3.52 |
Accounts Payable Turnover |
— | 1.62 | 0.02 | 0.05 | 0.14 | 0.16 | 0.05 | 0.12 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 283.22 | 14,633.18 | 11,808.24 | 2,927.56 | 1,818.05 | 8,764.45 | 1,918.48 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.00 | 0.00 | 1.57 | 4.63 | 8.79 | 5.75 | 0.02 |
Average Payables |
— | 0.59 | 0.59 | 0.82 | 1.37 | 1.30 | 1.51 | 1.42 |
Average Assets |
— | 11.63 | 19.03 | 80.91 | 131.68 | 105.89 | 84.01 | 87.25 |
Average Common Equity |
— | (116.10) | (116.10) | 6.50 | 118.75 | 84.55 | 58.98 | 61.61 |
Columns are period end dates